Drug Profile
AZD 5991
Alternative Names: AZD-5991Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Indoles; Naphthalenes; Organic sulfur compounds; Pyrazoles; Small molecules
- Mechanism of Action Apoptosis stimulants; MCL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 05 Dec 2023 Pharmacodynamics data from preclinical trial in Triple negative breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 08 Jun 2023 Safety and efficacy data from a phase I trial in Hematological malignancy presented at the 28th Congress of the European Hematology Association(EHA-2023)
- 30 Sep 2022 Discontinued - Phase-I/II for Haematological malignancies (Combination therapy, Second-line therapy or greater) in USA (IV) before September 2022 (AstraZeneca pipeline, November 2022)